MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Takeda Pharmaceutical Co Ltd ADR

Затворен

СекторЗдравеопазване

14.96 0.4

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.89

Максимум

15.03

Ключови измерители

By Trading Economics

Приходи

-68B

24B

Продажби

-32B

1.1T

P/E

Средно за сектора

34.581

63.778

EPS

0.048

Дивидентна доходност

4.39

Марж на печалбата

2.079

Служители

49,281

EBITDA

-4.3B

380B

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.39%

2.39%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

47B

Предишно отваряне

14.56

Предишно затваряне

14.96

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.01.2025 г., 11:02 ч. UTC

Печалби

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

30.01.2025 г., 07:53 ч. UTC

Печалби

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

28.01.2025 г., 00:03 ч. UTC

Горещи акции

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

31.10.2024 г., 07:27 ч. UTC

Печалби

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update

31.10.2024 г., 06:44 ч. UTC

Печалби

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance

31.07.2024 г., 07:19 ч. UTC

Печалби

Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue -- Update

31.07.2024 г., 06:29 ч. UTC

Печалби

Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue

17.06.2024 г., 13:34 ч. UTC

Значими двигатели на пазара

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

13.05.2024 г., 11:26 ч. UTC

Значими двигатели на пазара

AC Immunity Shares Soar on Exclusive License Deal with Takeda

9.05.2024 г., 07:37 ч. UTC

Печалби

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update

9.05.2024 г., 07:08 ч. UTC

Печалби

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss

30.01.2025 г., 07:12 ч. UTC

Печалби

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

30.01.2025 г., 07:08 ч. UTC

Печалби

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

30.01.2025 г., 06:42 ч. UTC

Печалби

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

30.01.2025 г., 06:40 ч. UTC

Печалби

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

30.01.2025 г., 06:36 ч. UTC

Печалби

Takeda: to Discontinue Soticlestat Development Program

30.01.2025 г., 06:34 ч. UTC

Печалби

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

30.01.2025 г., 06:32 ч. UTC

Печалби

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

30.01.2025 г., 06:31 ч. UTC

Печалби

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical Sees FY Net Y118.00B

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical Sees FY Net Y118.00B

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical Raises FY Dividend to Y196.00

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

30.01.2025 г., 06:30 ч. UTC

Печалби

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

Сравнение с други в отрасъла

Ценова промяна

Takeda Pharmaceutical Co Ltd ADR Прогноза

Консенсусна оценка

By TipRanks

0 ratings

0

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

14.89 / 15.155Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Strong Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.